http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-119030-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_64bc6fffe24afe2a70641bba221a4b74 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365 |
| filingDate | 2020-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a1d112efbc45d106adfb2eb40074345 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49032b50dcea8590f8e89c4b3d847a66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2932e6c978ae187337c62a2b29333cb2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8900f02752b1b1828f71c03441deff4f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87a2151918d4e54ee735aa39645a7d02 |
| publicationDate | 2021-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-119030-A1 |
| titleOfInvention | 5H-THIOCHROME[4,3-b]PYRIDIN-2-OXO-3-CARBOXYLATES OR THEIR DIOXO OR TRIOXO DERIVATIVES AND THEIR USE IN THE TREATMENT OR PROPHYLAXIS OF HEPATITIS B |
| abstract | 5H-thiochromene[4,3-b]pyridine-2-oxo-3-carboxylate compounds or their dioxo or trioxo derivatives, pharmaceutical compositions comprising them and their use in the treatment or prevention of Hepatitis B. Claim 1: A compound according to formula (1), wherein X is -S-, -S(=O)- or -S(=O)₂-; G is -OH or C₁₋₄ alkoxy; R¹ is monocyclic C₃₋₆ cycloalkyl unsubstituted or substituted with one or more independently selected halo or C₁₋₄ alkyl, or spirocyclic C₆₋₁₀ cycloalkyl unsubstituted or substituted with one or more independently selected halo or C₁₋₄ alkyl ; each R²ᵃ and R²ᵇ is independently selected from: H, C₁₋₄ alkyl, C₃₋₇ cycloalkyl unsubstituted or substituted with one or more, independently selected: C₁₋₄ alkyl unsubstituted or substituted with one or more, independently selected, halo, or C₁₋₄ alkoxy unsubstituted or substituted with one or more independently selected halo; and 4 to 7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N or S, unsubstituted or substituted by one or more, independently selected: C₁₋₄ alkyl unsubstituted or substituted by one or more, independently selected , halo, or C₁₋₄ alkoxy unsubstituted or substituted with one or more independently selected halo; or R²ᵃ and R²ᵇ together with the atom to which they are attached can form a C₃₋₇ cycloalkyl spirocyclic ring; R³ is halo, -OH, -CN, C₁₋₄ alkyl unsubstituted or substituted with one or more independently selected Rᵃ¹ groups, C₁₋₆ alkoxy unsubstituted or substituted with one or more independently selected Rᵃ¹ groups, non-phenyl substituted or substituted with one or more, independently selected, Rᵇ¹, 5- or 6-membered monocyclic heteroaryl comprising one or more heteroatoms independently selected from O, N, or S, where heteroaryl is unsubstituted or substituted with one or more, independently selected , Rᵇ¹, C₃₋₇ cycloalkyl, where cycloalkyl is unsubstituted or substituted by one or more, independently selected, Rᵇ¹, -O-C₃₋₇ cycloalkyl, where cycloalkyl is unsubstituted or substituted by one or more, independently selected, Rᵇ¹, 4 to 7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N or S, where heterocycloalkyl is unsubstituted or substituted with one or more, independently selected, Rᵇ¹, -O-(4- to 7-membered monocyclic heterocycloalkyl), where heterocycloalkyl comprises one or more heteroatoms independently selected from O, N, or S, and where heterocycloalkyl is unsubstituted or substituted with one or plus, independently selected, Rᵇ¹, -C(=O)NR⁶ᵃR⁶ᵇ, -NR⁶ᶜ-C(=O)-C₁₋₄-alkyl, -S(=O)₂NR⁶ᵈR⁶ᵉ, -NR⁶ᶠ-C(=O)O-C₁₋-alkyl ₄, or -NR⁶ᵍR⁶ʰ; R⁴ is H, -SO₂-C₁₋₄ alkyl, halo, CN, C₁₋₄ alkyl unsubstituted or substituted by one or more, independently selected, Rᵃ², phenyl unsubstituted or substituted by one or more, independently selected, Rᵇ², heteroaryl 5- or 6-membered monocyclic comprising one or more heteroatoms independently selected from O, N or S, where heteroaryl is unsubstituted or substituted with one or more independently selected Rᵇ², C₃₋₇ cycloalkyl, where cycloalkyl is unsubstituted or substituted with one or more, independently selected, Rᵇ², 4- to 7-membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N, or S, where heterocycloalkyl is unsubstituted or substituted with one or more, independently selected, Rᵇ², -C(=O)NR⁷ᵃR⁷ᵇ, -NR⁷ᶜ-C(=O)-C₁₋₄-alkyl, -S(=O)₂NR⁷ᵈR⁷ᵉ, -NR⁷ᶠ-C(=O)O-C₁₋₄-alkyl, or -NR⁷ᵍR⁷ʰ ; R⁵ is H, -N, halo, or C₁₋₄ alkyl unsubstituted or substituted with one or more independently selected halo; each R⁶ᵃ, R⁶ᵇ, R⁶ᶜ, R⁶ᵈ, R⁶ᵉ, R⁶ᶠ, R⁶ᵍ and R⁶ʰ is independently H or C₁₋₄ alkyl; each R⁷ᵃ, R⁷ᵇ, R⁷ᶜ, R⁷ᵈ, R⁷ᵉ, R⁷ᶠ, R⁷ᵍ and R⁷ʰ is independently H or C₁₋₄ alkyl unsubstituted or substituted with one -C(=O)OH; each Rᵃ¹ and Rᵃ² is independently: halo, -CN, -OH, -SO₂-C₁₋₄ alkyl, C₁₋₄ alkoxy, phenyl, 5- or 6-membered monocyclic heteroaryl comprising one or more heteroatoms independently selected from O, N or S, C₃₋₇ cycloalkyl unsubstituted or substituted with one or more, independently selected, R⁹ᵃ, 4- to 7-membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N or S, unsubstituted or substituted with one or more , independently selected, R⁹ᵇ, and 4 to 10 membered fused/spiro/bridged heterocycloalkyl comprising one or more heteroatoms independently selected from O, N, or S, unsubstituted or substituted by one or more, independently selected, R⁹ᶜ; each R⁹ᵃ, R⁹ᵇ and R⁹ᶜ is independently selected from: halo, -CN, -SO₂-C₁₋₄ alkyl, oxo, alkyl unsubstituted or substituted with one or more independently selected halo, -C₁₋₄ alkoxy or -OH, -C(=O)NR¹⁰ᵃR¹⁰ᵇ, -C₁₋₄ alkoxy, or -C(=O)C₁₋₄ alkyl; each Rᵇ¹ and Rᵇ² is independently selected from: halo, oxo, C₁₋₄ alkyl unsubstituted or substituted with a C₁₋₄ alkoxy or -C(=O)OH; C₁₋₄ alkoxy, and 4 to 7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N or S; and each R¹⁰ᵃ and R¹⁰ᵇ is independently H or C₁₋₄ alkyl; or a pharmaceutically acceptable salt thereof, solvate or pharmaceutically acceptable salt of solvate. |
| priorityDate | 2019-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.